BioImagene launches new Ki-67 algorithm for prostate image analysis
9 April 2009
BioImagene has launched a new Ki-67 prostate image analysis
algorithm. The algorithm, which is part of Virtuoso, its suite of
web-based software applications for digital pathology, is used to detect
and provide quantitative measurement of the protein biomarker Ki-67.
Research has shown that Ki-67 immunohistochemistry may be a valuable
predictor of biochemical relapse and distant metastasis after
prostatectomy and radiation therapy.
“The launch of the Ki-67 algorithm that can be used in a research
setting illustrates the potential impact digital pathology can have on
the practice of medicine,” commented Dr Ajit Singh, CEO BioImagene. “In
the coming months, we expect to launch a series of additional algorithms
to serve the pathology and research communities.”
The launch of the Ki-67 algorithm adds to the company’s growing
offering of image-analysis tools. BioImagene also has a PIN4 algorithm
for prostate cancer research, and FDA-cleared algorithms to assess
HER2/neu immunohistochemistry status. The iScan Coreo and associated
software are used to detect and provide a quantitative measurement of
HER2/neu, a protein measured in breast cancer patients to determine
their candidacy for treatment with the Genentech drug Herceptin.
Bookmark this page